Page results
-
UCLH has received excellent results in the 2023 National Adult Inpatient Survey this year, with patients rating their overall care 8.8 out of 10. This is an improvement on last year's score of 8.7 and once again makes us the best performing acute/combined trust in England.
-
This page has been written for children and young people and explains what deinfibulation is.
-
A lung cancer patient at UCLH is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.
-
This page tells you about having a Port-a-cath Insertion (implantable port) with the Interventional Radiology team.
-
UCLH is supporting a new UK-wide health and care research registry, as part of the nation’s biggest-ever recruitment drive to clinical trials.
-
Infection inpatients offers a variety of different specialities including Infectious Diseases and Tropical Medicine, Respiratory Medicine and Rheumatology. We are also the inpatient ward to the Hospital of Tropical Diseases.
-
With all eyes on Paris for this summer’s Olympic Games, we look at how UCLH’s Institute of Sport, Health and Exercise (ISEH) has supported one of Britian’s Olympic hopefuls, and the care it provides for all kinds of sportspeople, from professionals to weekend warriors.
-
Easy read information for patients living with a catheter.
-
This page provides information about achalasia and its diagnosis and treatment.
-
UCLH is one of the largest blood cancers treatment centres in Europe, with both inpatient beds and a comprehensive day care service. The service is the main treatment centre for patients from north and east London, and west Essex.
File results
-
FOI/2022/206 - Rates for Bonham Carter House 52-54 Gower Street
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services